PAH News

June 17, 2019June 17, 2019

Opsumit Shows Promise for Portopulmonary Hypertension in Phase 4 Trial

News, PAH News

Treatment for 12 weeks with Actelion Pharmaceuticals’ Opsumit (macitentan) significantly improved blood vessels’ resistance in patients with portopulmonary hypertension without causing further damage to the liver, data from the PORTICO ... Read more

June 13, 2019June 18, 2019

Exposure to Traffic-Related Air Pollutants Linked to Disease Severity in PAH, UK Study Shows

News, PAH News

Exposure to air pollutants may be linked to disease severity and other clinical outcomes in people with pulmonary arterial hypertension (PAH), a study shows. The study, “Traffic exposures, air ... Read more

June 12, 2019June 12, 2019

FDA Approves Novitium Pharma’s Generic Sildenafil for PAH Treatment

News, PAH News

The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma‘s generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension ... Read more

June 7, 2019June 7, 2019

Liquidia Moves Closer to Requesting FDA Approval of LIQ861 for PAH

News, PAH News

The latest INSPIRE Phase 3 trial data on LIQ861 as a treatment for pulmonary arterial hypertension (PAH) support the submission of a New Drug Application (NDA) with the U.S. ... Read more

May 31, 2019May 31, 2019

Results Support Therapeutic Intra-vascular Ultrasound (TIVUS) for PAH

News, PAH News

New data support the safety and effectiveness of TIVUS (therapeutic intra-vascular ultrasound) for patients with pulmonary arterial hypertension (PAH) on a stable treatment regimen. The data were recently presented at ... Read more

May 30, 2019May 30, 2019

Owlstone, Actelion Team Up to Develop Breath-based Test for Diagnosing PH

News, PAH News, PH News

Owlstone Medical has established a strategic collaboration with Actelion Pharmaceuticals to develop and validate a breath-based diagnostic test for different types of pulmonary hypertension (PH). Actelion Pharmaceuticals will solely fund this ... Read more

May 29, 2019May 29, 2019

Bayer US Launches $1 Million Grant Program to Boost Clinical Research into PH

CTEPH News, News, PAH News, PH News

The Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, recently launched by Bayer US, will grant up to $1 million dollars for clinical research into pulmonary hypertension (PH). Spread over two years, ... Read more

May 24, 2019June 18, 2019

Blood Vessel Changes in the Eyes Linked with Lung Vascular Damage in PAH, Study Finds

News, PAH News, PH News

A type of abnormality in small blood vessels of the eyes, called retinal vascular tortuosity, may provide a non-invasive way to detect alterations in lung circulation in patients with ... Read more

May 23, 2019June 18, 2019

Uptravi Beneficial Regardless of When Started, But More Effective if Started Early, Analysis Suggests

News, PAH News

A new analysis of Actelion‘s GRIPHON clinical trial indicates that Uptravi (selexipag) tablets reduce the risk of disease complications or death in patients with pulmonary arterial hypertension (PAH), regardless of ... Read more

May 20, 2019June 3, 2019

Resverlogix Announces Promising Findings on Apabetalone, Will Launch Phase 2 Trial in PAH Patients

News, PAH News

Promising preclinical findings recently published in a peer-reviewed journal opened the door to the launch of a Phase 2 trial testing the therapeutic potential of apabetalone (RVX-208), Resverlogix‘s proprietary ... Read more

Pin It on Pinterest